key: cord-0983099-fka2hcio
authors: Krajewski, Jennifer; Chen, Jing; Motiani, Juhi; Baer, Aryeh; Appel, Burton; Zakrzewski, Johannes; Hankewycz, Melanie; Durning, Nancy; Gillio, Alfred
title: Hematopoietic stem cell transplant in two pediatric patients testing positive for SARS‐CoV‐2: A case report
date: 2021-10-27
journal: Pediatr Transplant
DOI: 10.1111/petr.14179
sha: a497729cc5645fd9b1b57c1256c21619dc30f591
doc_id: 983099
cord_uid: fka2hcio

BACKGROUND: The SARS‐CoV‐2 pandemic brought challenges to all areas of medicine. In pediatric bone marrow transplant (BMT), one of the biggest challenges was determining how and when to transplant patients infected with SARS‐CoV‐2 while mitigating the risks of COVID‐related complications. METHODS: Our joint adult and pediatric BMT program developed protocols for performing BMT during the pandemic, including guidelines for screening and isolation. For patients who tested positive for SARS‐CoV‐2, the general recommendation was to delay BMT for at least 14 days from the start of infection and until symptoms improved and the patient twice tested negative by polymerase chain reaction (PCR). However, delaying BMT in patients with malignancy increases the risk of relapse. RESULTS: We opted to transplant two SARS‐CoV‐2 persistently PCR positive patients with leukemia at high risk of relapse. One patient passed away early post‐BMT of a transplant‐related complication. The other patient is currently in remission and doing well. CONCLUSION: These cases demonstrate that when the risk associated with delaying BMT is high, it may be reasonable to proceed to transplant in pediatric leukemia patients infected with SARS‐CoV‐2.

Patient 1 was a 16-year-old boy who was originally diagnosed at age 10.5 years with National Cancer Institute (NCI) high-risk B-cell acute lymphoblastic leukemia (ALL) with CNS3 disease. He was treated on a Children's Oncology Group (COG) study for high-risk ALL (AALL1131). End of induction minimal residual disease (MRD) level was 1.3% by multiparameter flow cytometry, though he achieved negative MRD by the end of consolidation. He, therefore, continued with chemotherapy alone, and also received 1800 cGy cranial radiation for treatment of CNS3 disease. Cytogenetics at the time of diagnosis showed that he had a CRLF2-rearrangement, consistent with Ph-like ALL. Subsequent course was complicated by an isolated central nervous system (CNS) relapse during the maintenance phase of chemotherapy. He enrolled onto COG AALL1331, a phase III study for first relapse of B-ALL, was considered low-risk and was randomized to receive conventional chemo without Blinatumomab, and also received an additional 1800 cGy cranial RT. Sixteen months after CAR-T infusion, he presented with intermittent left shoulder pain for 6 weeks. CT of the chest showed a left lung apex soft tissue mass with mediastinal adenopathy. Core biopsy confirmed an extramedullary relapse of CD19 + pre-B-cell ALL.

Genomic sequencing of the relapsed tissue again showed CRLF2rearrangement, consistent with his original diagnosis of Ph-like ALL.

Bone marrow revealed 0.081% CD19+ blasts and CSF was negative.

The plan at that time was for chemotherapeutic bridge to BMT, but due to developing Staphylococcus aureus sepsis with microabscesses, a second CAR-T infusion was done instead, with complete remission prior to infusion.

Evaluation for matched unrelated donor (MUD) BMT was still in process in January 2021, when the patient developed low-grade fever and symptoms of a mild upper respiratory infection. On January 15, 2021, SARS-CoV-2 PCR was positive, and he was diagnosed with COVID-19. He was admitted and received a dose of convalescent plasma, but never developed an oxygen requirement or respiratory support so did not receive any additional treatment for COVID-19. His SARS-CoV-2 IgG antibody remained negative, and he Echocardiogram showed mildly reduced biventricular systolic function. In addition to pancytopenia, the patient's labs were notable for ferritin 5622 ng/ml, C-reactive protein (CRP) 24.3 mg/dl, Troponin 0.25 ng/ml, brain natriuretic peptide (BNP) 4437 pg/ml, total bilirubin 4 mg/dl, albumin 2.7 g/dl, and INR 2.09. Blood cultures and other infectious studies remained negative. High dose IVIG and methylprednisolone were ordered for the treatment of possible MIS-C on day +13, but due to deteriorating clinical status and multiorgan failure due to progressive SOS, the patient's family requested an Allow Natural Death order. He subsequently passed away later that day.

Patient #2 is a now 18-month-old girl who was diagnosed with mixed phenotype acute leukemia (B/myeloid MPAL) at 3 months of age and initiated treatment with five-drug induction chemotherapy as per COG AALL15P1. Following induction, consolidation, and blinatumomab treatments, she still had persistent MRD, so was referred for CAR-T as a bridge to BMT. Prior to planned CAR-T a small lump appeared on her scalp. MRI showed a midline mass with bilateral maxillary and soft tissue involvement, and biopsy confirmed extramedullary relapse. Initial T cell apheresis for CAR-T was aborted early due to rapidly progressive leukemia that required chemotherapy treatment. After completing bridging chemotherapy, the extramedullary disease resolved, though she still had persistent marrow involvement. The second T cell apheresis was successful, and she received her CAR-T infusion after lymphodepleting chemotherapy. Treatment was complicated by grade 2 CRS requiring PICU admission and tocilizumab. Day +30 post-infusion bone marrow showed 3.6% residual B-ALL. Despite re-induction chemotherapy, she developed a large right pleural effusion, confirmed to be malignant, and had persistent marrow disease. While inpatient for fever and neutropenia, the patient's mother, her bedside caregiver, treated with convalescent plasma given her immunocompromised status. After multiple salvage chemotherapy regimens over a total period of 11 months, the patient finally achieved an MRD-negative remission. Her PCR test remained positive for SARS-CoV-2, so the transplant team discussed with her family the potential risks of undergoing BMT while still SARS-CoV-2 positive. Given her extremely refractory, very high-risk leukemia, the decision was made to proceed to BMT quickly since she had finally achieved an MRD-negative remission. Screening chest X-ray was done before conditioning was started, which showed a hazy opacification at the right lung base. prednisolone. Her absolute neutrophil count recovery was noted on day +20, and she was discharged on day +28. One month post-BMT, she achieved full donor chimerism with no evidence of leukemia. She required steroids for mild acute skin graft versus host disease, but it has remained quiescent on tapering steroids. She has not had any further symptoms related to SARS-CoV-2 infection, and she had a negative SARS-CoV-2 PCR on day +40 and day +47, allowing for discontinuation of isolation precautions.

The COVID-19 global pandemic has upended the practice of medicine across specialties. When considering whether to take these two high-risk patients to BMT while still PCR positive for SARS-CoV-2, Three-year OS following relapse in infant ALL is approximately 20.9%, with slight improvement to 24.9% in infants treated with curative intent. 10 Those with early relapses and bone marrow involvement (either isolated or combined) had worse outcomes. 6 Outcome following relapses for infant B-ALL is still inferior to outcome following relapses for childhood B-ALL, even in the setting of more contemporary clinical trials. 11 The decision to proceed with or delay BMT in the setting of a positive SARS-CoV-2 PCR should be determined on an individual basis. Despite the positive SARS-CoV-2 infections by PCR, BMT was still planned for both patients because of the high risk of relapse with BMT offering the best chance of cure after having already received multiple lines of therapies. Although antigen directed therapies such as Blinatumomab, a CD 19 directed therapy, and Inotuzumab, a CD22 directed therapy, could be considered while awaiting a negative SARS-CoV-2 test to proceed to BMT, both patients had already received antigen directed therapy without achieving a durable remission. Targeted therapies with Ruxolitinib against CRLF2-rearrangement for Patient 1 or menin inhibitor against KMT2A-rearrangement for Patient 2 could also be considered. Although both targeted therapies against genomic abnormalities and antigen directed therapies are considered less intensive and better tolerated and may minimize complications of COVID-19 compared to conventional chemotherapy or BMT, neither were likely to induce a durable remission adequate enough to bridge to BMT. In addition, both patients had histories of extensive extramedullary disease that are generally not sufficiently treated by targeted treatments alone.

The two patients in this report are the first described in the literature treated with BMT while still positive for SARS-CoV-2 infection by PCR. Patient 1 passed away due to SOS, a known complication in BMT patients treated with Busulfan. His death did not seem to be related to SARS-CoV-2, but it is unclear if developing MIS-C contributed to his SOS. Treatment for possible MIS-C was planned but was held when the family opted to not escalate care further. Patient 2 developed a febrile hyperinflammatory syndrome consistent with MIS-C, and rapidly improved following IVIG and high dose steroid treatment currently recommended for MIS-C. She remains in remission more than 100 days post-BMT. Our experience demonstrates the importance of considering complications of SARS-CoV-2 infection in patients following BMT. Despite the potential for complications, the benefit of transplant in patients with high risk of relapse who are persistently positive for SARS-CoV-2 by PCR may outweigh the risks involved, but more patient experiences are necessary to determine this. Our limited experience demonstrates that it may be reasonable to proceed to BMT in patients with persistent positive SARS-CoV-2 PCR as long as MIS-C is kept in the differential for fever and other inflammatory complications during the post-BMT period.

None of the authors have any conflicts of interest to disclose.

Each author contributed equally and independently to the manuscript.

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study as this is a case report.

https://orcid.org/0000-0002-6226-965X

Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients

Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance

COVID-19-associated multisystem inflammatory syndrome in children-United States

Multisystem inflammatory syndrome in U.S. children and adolescents

American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children's Oncology Group (COG) study